期刊
AMERICAN JOURNAL OF PSYCHIATRY
卷 163, 期 1, 页码 153-155出版社
AMER PSYCHIATRIC PUBLISHING, INC
DOI: 10.1176/appi.ajp.163.1.153
关键词
-
类别
资金
- Intramural NIH HHS Funding Source: Medline
- NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002857, Z01MH002857] Funding Source: NIH RePORTER
Objective: This study was designed to assess possible antidepressant effects of memantine, a selective N-methyl-D-aspartate ( NMDA) receptor antagonist in humans. Method: In a double-blind, placebo-controlled study, 32 subjects with major depression were randomly assigned to receive memantine (5-20 mg/day) (N = 16) or placebo (N = 16) for 8 weeks. Primary efficacy was assessed by performance on the Montgomery-Asberg Depression Rating Scale (MADRS). Results: The linear mixed models for total MADRS scores showed no treatment effect. Conclusions: In an 8-week trial, the low-to-moderate-affinity NMDA antagonist memantine in doses of 5-20 mg/day was not effective in the treatment of major depressive disorder.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据